{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:40:41Z","timestamp":1787240441740,"version":"build-2736575974"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    We systematically reviewed whether BIAs for anticancer drugs consider the scope of costs rationally and compared the results of different cost scopes to provide suggestions for future analyses and decision-making.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Eligible BIAs published in PubMed, Embase, Web of Science, and the Cochrane Library from 2016 to 2021 were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We extracted 15 terms from the included studies and analyzed how they considered the scope of costs. In addition, a budget impact model was developed for the introduction of geptanolimab to China's National Reimbursement Drug List to enable a comparison of two cost-scope scenarios.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 29 studies were included in the systematic review. All 29 studies considered the costs of anticancer drugs, and 25 (86%) also considered condition-related costs, but only 11 (38%) considered subsequent treatment costs. In the comparative study, the predicted budget impacts from 2022 to 2024 were significantly impacted by subsequent treatment costs, with annual differences between the two cost-scope scenarios of $39,546,664, $65,866,161, and $86,577,386, respectively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The scope of costs considered in some existing BIAs for anticancer drugs are not rational. The variations between different cost scopes in terms of budget impact were significant. Thus, BIAs for anticancer drugs should consider a rational scope of costs that adheres to BIA guidelines. Researchers and decision-makers should pay more attention to the scope of costs to achieve better-quality BIAs for anticancer drugs and enhance reimbursement decision-making.\n                  <\/jats:p>","DOI":"10.3389\/fpubh.2021.777199","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T02:06:11Z","timestamp":1636077971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Yue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3945\/an.116.012211","article-title":"World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015","volume":"7","author":"McGuire","year":"2016","journal-title":"Adv Nutr."},{"key":"B2","volume-title":"WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All","year":"2020"},{"key":"B3","unstructured":"Advancing Health through Innovation: New Drug Approvals 2019"},{"key":"B4","unstructured":"National Medical Products Administration2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib5010001","article-title":"Taking up cancer immunotherapy challenges: bispecific antibodies, the path forward?","volume":"5","author":"Del","year":"2015","journal-title":"Antibodies."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3390\/ijms22042008","article-title":"Therapeutic advances in oncology","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10198-011-0348-5","article-title":"Budget impact analysis in economic evaluation: a proposal for a clearer definition","volume":"12","author":"Garattini","year":"2011","journal-title":"Eur J Health Econ."},{"key":"B10","author":"Mauskopf","year":"2017"},{"key":"B11","unstructured":"Pharmacoeconomic Guidelines Around the World.2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.18553\/jmcp.2005.11.1.66","article-title":"Health plan budget impact analysis for pimecrolimus","volume":"11","author":"Chang","year":"2005","journal-title":"J Manag Care Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.clinthera.2008.04.016","article-title":"Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer","volume":"30","author":"Danese","year":"2008","journal-title":"Clin Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","article-title":"Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2013budget impact analysis","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health."},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12962-020-00253-5","article-title":"A systematic review of the budget impact analyses for antitumor drugs of lung cancer","volume":"18","author":"Han","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40258-021-00652-6","article-title":"Systematic \u2026\u2026 assessment [published online ahead of print, 2021 May 6]","volume":"19","author":"Chugh","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"B19","unstructured":"Assessing Resource Impact Process Manual: Technology Appraisals and Highly Specialised Technologies2017"},{"key":"B20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00019053-200826060-00003","article-title":"Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada","volume":"26","author":"Marshall","year":"2008","journal-title":"Pharmacoeconomics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40273-017-0602-5","article-title":"The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)","volume":"36","author":"Ghabri","year":"2018","journal-title":"Pharmacoeconomics."},{"key":"B22","volume-title":"Guidelines for the Budget Impact Analysis of Health Technologies in Ireland","year":"2018"},{"key":"B23","unstructured":"Guidelines for Preparing a Submission to the PBAC. Version 4. Draft for Public Consultation2006"},{"key":"B24","volume-title":"Guideline for Economic Evaluations in Healthcare","year":"2016"},{"key":"B25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1179\/2295333714Y.0000000118","article-title":"Belgian guidelines for budget impact analyses","volume":"70","author":"Neyt","year":"2015","journal-title":"Acta Clin Belg."},{"key":"B26","first-page":"65","article-title":"Budget impact analysis","volume":"97","author":"Leelahavarong","year":"2014","journal-title":"J Med Assoc Thai"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2004.71257.x","article-title":"Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries","volume":"7","author":"Orlewska","year":"2004","journal-title":"Value Health."},{"key":"B28","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40258-013-0064-7","article-title":"A critical systematic review of budget impact analyses on drugs in the EU countries","volume":"12","author":"van de Vooren","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1586\/14737167.2016.1159958","article-title":"Budget impact analysis of medicines: updated systematic review and implications","volume":"16","author":"Faleiros","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B31","unstructured":"National Bureau of China.2020"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B33","first-page":"1039","article-title":"Updated interpretation of guidelines for peripheral T-cell and NK\/T-cell lymphoma","volume":"47","author":"Gao","year":"2020","journal-title":"Chin J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B35","unstructured":"Annual Report 2020.2020"},{"key":"B36","unstructured":"2021"},{"key":"B37","unstructured":"2021"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol."},{"key":"B40","unstructured":"2021"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","article-title":"NCCN guidelines insights: T-cell lymphomas, version 1","volume":"18","author":"Horwitz","year":"2020","journal-title":"J Natl Compreh Cancer Netw."},{"key":"B42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.18553\/jmcp.2020.20330","article-title":"Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer","volume":"27","author":"Appukkuttan","year":"2021","journal-title":"J Manag Care Spec Pharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13696998.2020.1867470","article-title":"Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States","volume":"24","author":"Cai","year":"2021","journal-title":"J Med Econ."},{"key":"B44","first-page":"15","article-title":"Budget impact of adaptive Abiraterone therapy for castration-resistant prostate cancer","volume":"14","author":"Mason","year":"2021","journal-title":"Am Health Drug Benefits"},{"key":"B45","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1080\/13696998.2021.1942017","article-title":"Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States","volume":"24","author":"Stargardter","year":"2021","journal-title":"J Med Econ."},{"key":"B46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40273-020-00970-y","article-title":"The budget impact of including Rucaparib on a US payer formulary for the treatment of patients with metastatic ovarian cancer","volume":"39","author":"Wallace","year":"2021","journal-title":"Pharmacoeconomics."},{"key":"B47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/vaccines8040730","article-title":"Budget impact analysis of fixed dose versus weight-based dosing regimen of nivolumab and pembrolizumab in the treatment of non-small cell lung cancer","volume":"8","author":"Monirul","year":"2020","journal-title":"Vaccines"},{"key":"B48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.18553\/jmcp.2020.19329","article-title":"Budget impact of enzalutamide for nonmetastatic castration-resistant prostate cancer","volume":"26","author":"Schultz","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1111\/cas.14430","article-title":"Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients","volume":"111","author":"Yamazaki","year":"2020","journal-title":"Cancer Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2147\/CEOR.S215069","article-title":"Budget impact of including avelumab as a second-line treatment for locally advanced or metastatic urothelial cancer in the United States: commercial and medicare payer perspectives","volume":"11","author":"Kongnakorn","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2217\/cer-2018-0069","article-title":"Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy","volume":"8","author":"Neeser","year":"2019","journal-title":"J Comp Eff Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.18553\/jmcp.2019.25.11.1227","article-title":"Budget Impact of Dabrafenib and Trametinib in combination as adjuvant treatment of BRAF V600E\/K mutation-positive melanoma from a U.S. commercial payer perspective","volume":"25","author":"Stellato","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"B53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/13696998.2018.1557199","article-title":"Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US","volume":"22","author":"Wu","year":"2019","journal-title":"J Med Econ."},{"key":"B54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.18553\/jmcp.2018.24.6.534","article-title":"The budget impact of including Necitumumab on the formulary for first-line treatment of metastatic squamous non-small cell lung cancer: U.S. commercial payer and medicare perspectives","volume":"24","author":"Bly","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"B55","doi-asserted-by":"publisher","first-page":"544","DOI":"10.18553\/jmcp.2018.24.6.544","article-title":"Budget impact analysis of Afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a US health plan","volume":"24","author":"Graham","year":"2018","journal-title":"J Manag Care Spec Pharm."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1080\/03007995.2018.1503484","article-title":"Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+\/HER2- advanced or metastatic breast cancer","volume":"34","author":"Mistry","year":"2018","journal-title":"Curr Med Res Opin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"djx063","DOI":"10.1093\/jnci\/djx063","article-title":"A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer","volume":"109","author":"Goldstein","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B58","doi-asserted-by":"publisher","first-page":"991","DOI":"10.18553\/jmcp.2016.22.8.991","article-title":"Estimating the economic impact of adding panobinostat to a U.S. formulary for relapsed and\/or refractory multiple myeloma: a budget impact and cost-benefit model","volume":"22","author":"Bloudek","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"B59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.18553\/jmcp.2016.22.2.163","article-title":"Budget impact of enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"22","author":"Bui","year":"2016","journal-title":"J Manag Care Spec Pharm."},{"key":"B60","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40258-020-00626-0","article-title":"The budget impact of monoclonal antibodies used to treat metastatic colorectal cancer in Minas Gerais, Brazil","volume":"19","author":"Da","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14737167.2021.1860024","article-title":"Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients","volume":"21","author":"Elsamany","year":"2021","journal-title":"Expert Rev Pharm Out."},{"key":"B62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10198-020-01186-9","article-title":"Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations","volume":"21","author":"Westerink","year":"2020","journal-title":"Eur J Health Econ."},{"key":"B63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7399\/fh.10904","article-title":"Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain","volume":"42","author":"Delgado-Ortega","year":"2018","journal-title":"Farm Hosp"},{"key":"B64","doi-asserted-by":"publisher","first-page":"416","DOI":"10.18553\/jmcp.2017.23.4.416","article-title":"Budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer","volume":"23","author":"Flannery","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1136\/esmoopen-2017-000222","article-title":"Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis","volume":"2","author":"Norum","year":"2017","journal-title":"ESMO Open"},{"key":"B66","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/CEOR.S140866","article-title":"Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals","volume":"9","author":"Ortendahl","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/cam4.3690","article-title":"Home-based chemotherapy for stage III colon cancer patients in Thailand: cost-utility and budget impact analyses","volume":"10","author":"Kulthanachairojana","year":"2021","journal-title":"Cancer Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clcc.2021.04.001","article-title":"Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis","volume":"20","author":"Hanna","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hed.25481","article-title":"Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and\/or metastatic head and neck cancer","volume":"41","author":"Mennini","year":"2019","journal-title":"Head Neck"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.2217\/fon-2018-0904","article-title":"Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer","volume":"15","author":"Mennini","year":"2019","journal-title":"Future Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.vhri.2018.12.003","article-title":"In the era of cost-effectiveness analysis, affordability is a limiting factor for patients' access to innovative cancer treatments","volume":"20","author":"Aguiar","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"B73","doi-asserted-by":"publisher","first-page":"165721","DOI":"10.1016\/j.bbadis.2020.165721","article-title":"Metabolic reprogramming and disease progression in cancer patients","volume":"1866","author":"Torresano","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10147-020-01684-z","article-title":"Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy","volume":"25","author":"Iwasa","year":"2020","journal-title":"Int J Clin Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40258-021-00637-5","article-title":"Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from US commercial and medicare payer perspectives","volume":"19","author":"Yang","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40259-020-00461-8","article-title":"Budget impact analysis of the introduction of rituximab and trastuzumab intravenous biosimilars to EU-5 markets","volume":"35","author":"Jang","year":"2021","journal-title":"Biodrugs."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40273-017-0529-x","article-title":"Assessing the value of biosimilars: a review of the role of budget impact analysis","volume":"35","author":"Simoens","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"B79","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40258-019-00475-6","article-title":"Budget impact analysis of cancer screening: a methodological review","volume":"17","author":"Jahn","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"B80","doi-asserted-by":"publisher","first-page":"630949","DOI":"10.3389\/fphar.2021.630949","article-title":"Methodological quality assessment of budget impact analyses for orphan drugs: a systematic review","volume":"12","author":"Abdallah","year":"2021","journal-title":"Front Pharmacol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.777199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T02:06:22Z","timestamp":1636077982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.777199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":80,"alternative-id":["10.3389\/fpubh.2021.777199"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.777199","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"article-number":"777199"}}